2010 Volume 49 Issue 1 Pages 26-32
We evaluated efficacy in quality of life (QOL) in allergen-specific subcutaneous (SCIT) or sublingual (SLIT) immunotherapy for adult subjects with Japanese cedar pollinosis compared to drug therapy. Subjects involved 31 cases of SCIT, 40 of SLIT, 25 of in initial prescattering drug treatment, and 40 for whom medication was started after pollen scattering evaluated by the Japan rhinoconjunctivitis QOL questionnaire consisted of 6 symptoms and 17 items. Average scores are given for symptoms and QOL items numbered in the sequence of SCIT, SLIT, initial drug therapy, and postscattering therapy. SCIT was significantly better than SLIT for 3 items, but not significantly so for symptoms. SCIT was significantly better than initial drug therapy for rhinorrhea and eye symptoms and for 6 QOL items. SCIT was significantly better than postscattering therapy for all symptoms and for all QOL items except one. SLIT was superior to initial drug therapy in general, but not statistically significantly so for symptoms or QOL. SLIT was significantly better for all symptoms except sneezing and for 10 QOL items. These results suggest that immunotherapy had benefits for QOL and clinical efficacy.
